<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1510">
  <stage>Registered</stage>
  <submitdate>26/03/2007</submitdate>
  <approvaldate>26/03/2007</approvaldate>
  <nctid>NCT00453375</nctid>
  <trial_identification>
    <studytitle>Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus</studytitle>
    <scientifictitle>A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 With Open Label Cross-Over in Subjects With Type I Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BHT-3021-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Hypoglycemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BHT-3021
Treatment: drugs - BHT-Placebo

Experimental: 1 - BHT-3021

Placebo Comparator: 2 - BHT-Placebo


Treatment: drugs: BHT-3021
Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.

Treatment: drugs: BHT-Placebo
Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint in this study is safety.Safety parameters include: stimulated C-peptide response levels, opthalmologic examination, laboratory assessments, 24-hr urine protein, allergic reactions and adverse events including hypoglycemia.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary endpoints are pharmacodynamic parameters. Parameters include plasmid levels and insulin mRNA levels in blood and urine, Stimulated C-peptide response and Immunological response.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Diagnosis of Type 1a Diabetes Mellitus based on ADA Criteria

          -  =5 years since T1D was diagnosed

          -  = 18 years of age

          -  = 40 years of age at the time of diagnosis of Type 1a diabetes

          -  Presence of antibodies to at least one of the following antigens:

        insulin, GAD-65, or IA-2

          -  Detectable fasting C-peptide level

          -  C-peptide increase during screening mixed meal tolerance test with a minimal
             stimulated value of = 0.2 pmol/mL

          -  Presence of antibodies to at least one of the following antigens: insulin, GAD-65, or
             IA-2. If insulin antibody positive only, determination must be within 2 weeks of
             insulin initiation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  BMI &gt; 30 kg/m2

          -  Unstable blood sugar control defined as one or more episodes of severe hypoglycemia
             (defined as hypoglycemia that required the assistance of another person) within the
             last 30 days

          -  Current use of inhalable insulin

          -  Previous immunotherapy for T1D

          -  Administration of an experimental agent for T1D at any time or use of an experimental
             device for T1D within 30 days prior to screening, unless approved by the medical
             monitor

          -  History of any organ transplant, including islet cell transplant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>80</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC,WA</recruitmentstate>
    <hospital>Peninsula Clinical Research Centre - Kippa Ring</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Eastern Clinical Research Unit - Ringwood East</hospital>
    <hospital>Fremantle Hospital - Fremantle</hospital>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3050 - Ringwood East</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Waikato</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayhill Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety of BHT-3021 injections given weekly for
      12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to
      autoantigens (e.g. insulin). Changes in pancreatic beta cell function, insulin requirements
      and blood glucose levels will also be evaluated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00453375</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Gottlieb, MD</name>
      <address>University of Colorado, Denver</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>